Oral Health and Survivorship: Late Effects of Cancer and Cancer Therapy

  • Joel B. Epstein
  • Barbara E. Murphy


Oral complications of cancer and cancer therapy during and following therapy affect oral function, quality of life (QOL), and general health. Prevention and management is required throughout the course of the disease from diagnosis to survivorship. While the impact of acute oral complications in cancer patients is generally recognized, the potential negative impact of late oral health problems on symptom burden, oral function, and overall health is underappreciated. As survivorship increases, there has been increased interest in late treatment effects. This chapter reviews late effects of cancer therapy with a focus on head and neck cancer patients and stem-cell transplantation.


Salivary Gland Oral Health Intensity Modulate Radiation Therapy Symptom Burden Oral Pain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008;359(11):1143–1154.PubMedCrossRefGoogle Scholar
  2. 2.
    Epstein JB, Emerton S, Kolbinson DA, Le N, Phillips N, Stevenson-Moore P, Osoba D. Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck 1999;21:1–11.PubMedCrossRefGoogle Scholar
  3. 3.
    Abendstein H, Nordgren M, Boysen M, et al. Quality of life and head and neck cancer: a 5 year prospective study. Laryngoscope Dec 2005;115(12):2183–2192.PubMedCrossRefGoogle Scholar
  4. 4.
    Nordgren M, Hammerlid E, Bjordal K, Ahlner-Elmqvist M, Boysen M, Jannert M. Quality of life in oral carcinoma: a 5-year prospective study. Head Neck 2008;30(4):461–470.PubMedCrossRefGoogle Scholar
  5. 5.
    de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA. Long-term quality of life of patients with head and neck cancer. Laryngoscope 2000;110(1):98–106.PubMedCrossRefGoogle Scholar
  6. 6.
    Oates JE, Clark JR, Read J, Reeves N, Gao K, Jackson M et al. Prospective evaluation of quality of life and nutrition before and after treatment for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2007;133:533–540.PubMedCrossRefGoogle Scholar
  7. 7.
    We Y, Hu WH, Xia YF, Ma J, Liu MZ, Cui NJ. Quality of life of nasopharyngeal carcinoma survivors in mainland China. Qual Life Res 2007;16:65–74.CrossRefGoogle Scholar
  8. 8.
    Jensen SB, Mouridsen HT, Bergmann OJ, Reibel J, Brunner RN, Nauntofle B. Oral mucosal lesions, microbial changes and taste disturbances induced by adjuvant chemotherpay in breast cancer patients. Oral Surg Oral Med Oral Pathol Radiol Endod 2008;106:217–226.CrossRefGoogle Scholar
  9. 9.
    Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993;72(5):1612–1617.PubMedCrossRefGoogle Scholar
  10. 10.
    Brand HS, Bots CP, Raber-Durlacher JE. Xerostomia and chronic oral complications among patients treated with haematopoietic stem cell transplantation. Br Dent J 2009 Nov 14;207(9):E17; discussion 428–9.Google Scholar
  11. 11.
    Epstein JB, Raber-Durlacher JE, Wilkins A, Chavarria MG, Myint H. Advances in hematologic stem cell transplant: an update for oral health care providers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107(3):301–312.PubMedCrossRefGoogle Scholar
  12. 12.
    Flowers MED, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002;100:415–419.PubMedCrossRefGoogle Scholar
  13. 13.
    Kruse AL, Gratz KW. Oral carcinoma after hematopoietic stem cell transplantation-a new classification based on a literature review over 30 years. Head Neck Oncol 22 July 2009;1:29.Google Scholar
  14. 14.
    Imanguli MM, Alevizos I, Brown R, Pavletic SZ, Atkinson JC. Oral graft versus host disease. Oral Dis 2008;14:396–412.PubMedCrossRefGoogle Scholar
  15. 15.
    Wasserman TH, Brizel DM, Henke M, Monnier A, et al. Influence of intravenous amifostine on xerostomia, tumore control and survival after radiotherapy for head and neck cancer: a two year follow-up. Int J Radiat Oncol Biol Phys 2005;63:985–990.PubMedCrossRefGoogle Scholar
  16. 16.
    Buentzel J, Glatzel M, Mucke R, Micke O, Bruns F. Influence of amifostine on late radiation-toxicity in head and neck cancer: A follow-up study. Anticancer Res 2007;27:1953–1956.Google Scholar
  17. 17.
    Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients receiving cancer treatment. Cochrane Data Base Systematic Rev Oct 17, 2007;4:CD000978.Google Scholar
  18. 18.
    Law A, Kennedy T, Pellitteri P, Wood C, Christie D, Yumen O. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. Dec 1 2007;69(5):1361–1368.Google Scholar
  19. 19.
    Scarantino C, LeVeque F, Swann RS, White R, Schulsinger A et al. Effect of pilocarpine during radiation therapy: results of RTOG 97-09a phase III randomized study in head and neck cancer patients. J Support Oncol 2006;4:252–258.PubMedGoogle Scholar
  20. 20.
    Burlage FR, Roesink JM, Kampinga HH, Coppes RP, Terhaard C, Langendijk JA, van Luijk P, Stokman MA, Vissink A. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study. Int J Radiat Oncol Biol Phys Jan 1 2008;70(1):14–22.Google Scholar
  21. 21.
    Chambers MS, Jones CU, Biel MA, et al. Open-label, long-term safety study of cevimeline in the treatment of post-irradiation xerostomia. Int J Radiat Oncol Biol Phys 2007;69(5):1369–1376.PubMedCrossRefGoogle Scholar
  22. 22.
    Chambers MS, Posner M, Jones CU, et al. Cevimeline for the treatment of post-irradiation xerostomia in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. Jul 15 2007;68(4): 1102–1109.Google Scholar
  23. 23.
    Seikaly H, Jha N, Harris JR, Barnaby P, Liu R, Williams D, McGaw T, Reiger J, Wolfaardt J, Hanson J. Long-term outcomes of submandibular gland transfer for prevention of postradiation xerostomia. Arch Otolaryngol 2004;130(8):956–961.CrossRefGoogle Scholar
  24. 24.
    Henson BS, Inglehart MR, Eisbruch A, Ship JA. Preserved salivary output and xerostomia related quality-of-life in head and neck cancer patients receiving parotid-sparing radiotherapy. Oral Oncol 2001;1:84–93.CrossRefGoogle Scholar
  25. 25.
    Lin A, Kim HM, Terrell JE, Dawson LA, Ship JA, Eisbruch A. Quality of life after parotid sparing IMRT for head and neck cancer: A prospective longitudinal study. Int J Radiat Oncol Biol Phys 2003;57(12):61–70.PubMedCrossRefGoogle Scholar
  26. 26.
    Pacholke HD, Amdur RJ, Morris CG, et al. Late xerostomia after intensity-modulated radiation therapy versus conventional radiotherapy. Am J Clin Oncol 2005;28(4):351–358.PubMedCrossRefGoogle Scholar
  27. 27.
    Schubert MM, Correa ME. Oral graft versus host disease. Dent Clin North Am 2008;52:79–109.PubMedCrossRefGoogle Scholar
  28. 28.
    Epstein JB, Elad S, Eliav E, Jurevic R, Benoliel R, Orofacial pain in cancer Part II: clinical perspectives and management. J Dent Res 2007;86:506–18.PubMedCrossRefGoogle Scholar
  29. 29.
    Yamashita H, Nakagawa K, Hosoi Y, Kurokawa A, Fukuda Y, Matsumoto I, Misaka T, Abe K. Umami taste dysfunction in patients receiving radiotherapy for head and neck cancer. Oral Oncol 2009;45:e19–e23.PubMedCrossRefGoogle Scholar
  30. 30.
    Shi HB, Masuda M, Umezaki T, Kuratomi Y, Yamamoto T, Komiyama S. Irradiation impairment of umami taste in patients with head and neck cancer. Auris Nasus Larynx 2004;31:401–406.PubMedCrossRefGoogle Scholar
  31. 31.
    Peregrin T. Improving taste sensation in patients who have undergone chemotherapy or radiation therapy. J Am Diet Assoc 2006;106:15–40.CrossRefGoogle Scholar
  32. 32.
    Yamahita H, Nakagawa K, Nakamura N, Abe K, Asakage T, et al. Relation between acute and late irradiation impairment of four basic tastes and irradiated tongue volume in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2006;66:1422–1429.CrossRefGoogle Scholar
  33. 33.
    Sandow PL, Hejrat-Yazdi M, Heft MW. Taste loss and recovery following radiation therapy. J Dent Res 2006;85:608–611.PubMedCrossRefGoogle Scholar
  34. 34.
    Halyard MY, Jatoi A, Sloan JA, Bearden JD 3rd, Vora SA, et al. Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys 2007;67:1318–1322.PubMedCrossRefGoogle Scholar
  35. 35.
    Dijkstra DU, Kalk WW, Roodenberg JL. Trismus in head and neck oncology: a systematic review. Oral Oncol 2004;40:879–889.PubMedCrossRefGoogle Scholar
  36. 36.
    Louse Kent M, Brennan MT, Noll JL, Fox PC, Burri SH, et al. Radiation-induced trismus in head and neck cancer patients. Support Care Cancer 2008;16:305–309.CrossRefGoogle Scholar
  37. 37.
    Gomez DR, Zhung JE, Bomez J, Chan K, Wu AJ, et al. Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers. Int J Radiat Oncol Biol Phys 2009;73:1096–1103.PubMedCrossRefGoogle Scholar
  38. 38.
    Hsiung CY, Huang EY, Ting HM, Huang HY. Intensity-modulated radiotherapy for nasopharyngeal carcinoma: the reduction of radiation-induced trismus. Br J Radiol 2008;81:809–814.PubMedCrossRefGoogle Scholar
  39. 39.
    Shulmann DH, Shipman B, Willis FB. Treating trismus with dynamic splinting: a cohort case series. Adv Ther 2008;25:9–16.CrossRefGoogle Scholar
  40. 40.
    Bhrany AD, Izzard M, Wood AJ, Futran ND. Coroniodectomy for the treatment of trismus in head and neck cancer patients. Laryngoscope 2007;117:1052–1056.CrossRefGoogle Scholar
  41. 41.
    Nieder C, Zimmermann FB, Adam M, Mools M. The role of pentoxyfilline as a modifier of radiation therapy. Cancer Treat Rev 2005;44:8–55.Google Scholar
  42. 42.
    Hartl DM, Cohen M, Julieron M, Marandas P, Janot F, Bourhis J. Botulinum toxin for radiation-induced facial pain and trismus. Otolaryngol Head Neck Surg 2008;138:459–463.PubMedCrossRefGoogle Scholar
  43. 43.
    Loesche WJ. Microbiology and treatment of halitosis. Curr Infect Dis Rep 2003;5:220–226.PubMedCrossRefGoogle Scholar
  44. 44.
    Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncology 2006;7:508–514.PubMedCrossRefGoogle Scholar
  45. 45.
    Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369–376.Google Scholar
  46. 46.
    Teng MS, Futran ND. Osteoradionecrosis of the mandible. Curr Opin Otolaryngol Head Neck Surg 2005;13:217–221.PubMedCrossRefGoogle Scholar
  47. 47.
    Pitak-Arnnop P, Sader R, et al. Management of osteoradionecrosis of the jaws: an analysis of evidence. Eur J Surg Oncol 2008 Oct;34(10):1123–1134.PubMedCrossRefGoogle Scholar
  48. 48.
    Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009;113:6263–6264.CrossRefGoogle Scholar

Copyright information

© Society for Imaging Informatics in Medicine 2010

Authors and Affiliations

  1. 1.Department of Oral Medicine and Diagnostic SciencesCollege of Dentistry and Head and Neck Surgery/OtolaryngologyChicagoUSA

Personalised recommendations